Prognostic Value of 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography Imaging for Patients with Prostate Cancer
Purpose: The purpose of this study was to investigate the prognostic value of measuring glucose metabolism of primary prostate cancer lesions, using 2-Deoxy-2-[F-18]Fluoro-D-Glucose positron emission tomography (FDG-PET). Procedures: Forty-two patients with prostate cancer were investigated with FDG...
Gespeichert in:
| Veröffentlicht in: | Molecular imaging and biology 2002, Vol.4 (1), p.99-104 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104 |
|---|---|
| container_issue | 1 |
| container_start_page | 99 |
| container_title | Molecular imaging and biology |
| container_volume | 4 |
| creator | Oyama, Nobuyuki Akino, Hironobu Suzuki, Yuji Kanamaru, Hiroshi Miwa, Yoshiji Tsuka, Harutoshi Sadato, Norihiro Yonekura, Yoshiharu Okada, Kenichiro |
| description | Purpose: The purpose of this study was to investigate the prognostic value of measuring glucose metabolism of primary prostate cancer lesions, using 2-Deoxy-2-[F-18]Fluoro-D-Glucose positron emission tomography (FDG-PET).
Procedures: Forty-two patients with prostate cancer were investigated with FDG-PET, and standardized uptake value (SUV) of the prostate was calculated. After PET study, radical prostatectomy was performed in 17 patients (RPT group), and endocrine therapy in 25 patients (ET group). Relapse-free survival curves were created by the Kaplan-Meier method.
Results: In the RPT group, the patients with high SUV had a poorer prognosis compared to those with low SUV (
P = 0.033). In the ET group, the patients with high SUV were likely to have a poorer prognosis with low significance at a level of
P = 0.087.
Conclusions: FDG-PET appeared to have a defined prognostic value for patients with prostate cancer undergoing radical prostatectomy, and more patients need to be studied for patients undergoing endocrine therapy. (Mol Imag Biol 2002;4:99–104) |
| doi_str_mv | 10.1016/S1095-0397(01)00065-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72912467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1095039701000656</els_id><sourcerecordid>72912467</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-75d894f68feaa1c8f2a3b1dfd17dd01f134ea8358b5953e179017f4ddd33933a3</originalsourceid><addsrcrecordid>eNqFkE9vEzEQxVcIREvhI4B8QnBw67HX--eEUNq0lSo1EoULQpZjj1Oj3XWwvUDEl8dtInHkNHN4M--9X1W9BnYKDJqzT8B6SZno23cM3jPGGkmbJ9UxdA2jnDH-tOxSNBQawY-qFyl9Zwxa4OJ5dQS1FB2T4rj6s4phM4WUvSFf9DAjCY5weo7h945y-nVJofu2HOYQAz2nl8NsQkKyCsnnGCZyMfqUfFnuwhg2UW_vd-R61Bs_bYgLkax09jjlRH75fE-KV8o6I1noyWB8WT1zekj46jBPqs_Li7vFFb25vbxefLyhRvAu01barq9d0znUGkznuBZrsM5Cay0DB6JG3QnZrWUvBULbl56uttYK0QuhxUn1dv93G8OPGVNWJbXBYdAThjmplvfA66YtQrkXmhI0RXRqG_2o404BUw_U1SN19UBdMVCP1FVT7t4cDOb1iPbf1QFzEXzYC7DU_OkxqmQKF4PWRzRZ2eD_Y_EX8qmR-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72912467</pqid></control><display><type>article</type><title>Prognostic Value of 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography Imaging for Patients with Prostate Cancer</title><source>Alma/SFX Local Collection</source><creator>Oyama, Nobuyuki ; Akino, Hironobu ; Suzuki, Yuji ; Kanamaru, Hiroshi ; Miwa, Yoshiji ; Tsuka, Harutoshi ; Sadato, Norihiro ; Yonekura, Yoshiharu ; Okada, Kenichiro</creator><creatorcontrib>Oyama, Nobuyuki ; Akino, Hironobu ; Suzuki, Yuji ; Kanamaru, Hiroshi ; Miwa, Yoshiji ; Tsuka, Harutoshi ; Sadato, Norihiro ; Yonekura, Yoshiharu ; Okada, Kenichiro</creatorcontrib><description>Purpose: The purpose of this study was to investigate the prognostic value of measuring glucose metabolism of primary prostate cancer lesions, using 2-Deoxy-2-[F-18]Fluoro-D-Glucose positron emission tomography (FDG-PET).
Procedures: Forty-two patients with prostate cancer were investigated with FDG-PET, and standardized uptake value (SUV) of the prostate was calculated. After PET study, radical prostatectomy was performed in 17 patients (RPT group), and endocrine therapy in 25 patients (ET group). Relapse-free survival curves were created by the Kaplan-Meier method.
Results: In the RPT group, the patients with high SUV had a poorer prognosis compared to those with low SUV (
P = 0.033). In the ET group, the patients with high SUV were likely to have a poorer prognosis with low significance at a level of
P = 0.087.
Conclusions: FDG-PET appeared to have a defined prognostic value for patients with prostate cancer undergoing radical prostatectomy, and more patients need to be studied for patients undergoing endocrine therapy. (Mol Imag Biol 2002;4:99–104)</description><identifier>ISSN: 1536-1632</identifier><identifier>EISSN: 1860-2002</identifier><identifier>DOI: 10.1016/S1095-0397(01)00065-6</identifier><identifier>PMID: 14538053</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>FDG-PET ; Glucose Metabolism ; Prognosis ; Prostate Cancer</subject><ispartof>Molecular imaging and biology, 2002, Vol.4 (1), p.99-104</ispartof><rights>2001 Elsevier Science Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c328t-75d894f68feaa1c8f2a3b1dfd17dd01f134ea8358b5953e179017f4ddd33933a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14538053$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oyama, Nobuyuki</creatorcontrib><creatorcontrib>Akino, Hironobu</creatorcontrib><creatorcontrib>Suzuki, Yuji</creatorcontrib><creatorcontrib>Kanamaru, Hiroshi</creatorcontrib><creatorcontrib>Miwa, Yoshiji</creatorcontrib><creatorcontrib>Tsuka, Harutoshi</creatorcontrib><creatorcontrib>Sadato, Norihiro</creatorcontrib><creatorcontrib>Yonekura, Yoshiharu</creatorcontrib><creatorcontrib>Okada, Kenichiro</creatorcontrib><title>Prognostic Value of 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography Imaging for Patients with Prostate Cancer</title><title>Molecular imaging and biology</title><addtitle>Mol Imaging Biol</addtitle><description>Purpose: The purpose of this study was to investigate the prognostic value of measuring glucose metabolism of primary prostate cancer lesions, using 2-Deoxy-2-[F-18]Fluoro-D-Glucose positron emission tomography (FDG-PET).
Procedures: Forty-two patients with prostate cancer were investigated with FDG-PET, and standardized uptake value (SUV) of the prostate was calculated. After PET study, radical prostatectomy was performed in 17 patients (RPT group), and endocrine therapy in 25 patients (ET group). Relapse-free survival curves were created by the Kaplan-Meier method.
Results: In the RPT group, the patients with high SUV had a poorer prognosis compared to those with low SUV (
P = 0.033). In the ET group, the patients with high SUV were likely to have a poorer prognosis with low significance at a level of
P = 0.087.
Conclusions: FDG-PET appeared to have a defined prognostic value for patients with prostate cancer undergoing radical prostatectomy, and more patients need to be studied for patients undergoing endocrine therapy. (Mol Imag Biol 2002;4:99–104)</description><subject>FDG-PET</subject><subject>Glucose Metabolism</subject><subject>Prognosis</subject><subject>Prostate Cancer</subject><issn>1536-1632</issn><issn>1860-2002</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqFkE9vEzEQxVcIREvhI4B8QnBw67HX--eEUNq0lSo1EoULQpZjj1Oj3XWwvUDEl8dtInHkNHN4M--9X1W9BnYKDJqzT8B6SZno23cM3jPGGkmbJ9UxdA2jnDH-tOxSNBQawY-qFyl9Zwxa4OJ5dQS1FB2T4rj6s4phM4WUvSFf9DAjCY5weo7h945y-nVJofu2HOYQAz2nl8NsQkKyCsnnGCZyMfqUfFnuwhg2UW_vd-R61Bs_bYgLkax09jjlRH75fE-KV8o6I1noyWB8WT1zekj46jBPqs_Li7vFFb25vbxefLyhRvAu01barq9d0znUGkznuBZrsM5Cay0DB6JG3QnZrWUvBULbl56uttYK0QuhxUn1dv93G8OPGVNWJbXBYdAThjmplvfA66YtQrkXmhI0RXRqG_2o404BUw_U1SN19UBdMVCP1FVT7t4cDOb1iPbf1QFzEXzYC7DU_OkxqmQKF4PWRzRZ2eD_Y_EX8qmR-g</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>Oyama, Nobuyuki</creator><creator>Akino, Hironobu</creator><creator>Suzuki, Yuji</creator><creator>Kanamaru, Hiroshi</creator><creator>Miwa, Yoshiji</creator><creator>Tsuka, Harutoshi</creator><creator>Sadato, Norihiro</creator><creator>Yonekura, Yoshiharu</creator><creator>Okada, Kenichiro</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2002</creationdate><title>Prognostic Value of 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography Imaging for Patients with Prostate Cancer</title><author>Oyama, Nobuyuki ; Akino, Hironobu ; Suzuki, Yuji ; Kanamaru, Hiroshi ; Miwa, Yoshiji ; Tsuka, Harutoshi ; Sadato, Norihiro ; Yonekura, Yoshiharu ; Okada, Kenichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-75d894f68feaa1c8f2a3b1dfd17dd01f134ea8358b5953e179017f4ddd33933a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>FDG-PET</topic><topic>Glucose Metabolism</topic><topic>Prognosis</topic><topic>Prostate Cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oyama, Nobuyuki</creatorcontrib><creatorcontrib>Akino, Hironobu</creatorcontrib><creatorcontrib>Suzuki, Yuji</creatorcontrib><creatorcontrib>Kanamaru, Hiroshi</creatorcontrib><creatorcontrib>Miwa, Yoshiji</creatorcontrib><creatorcontrib>Tsuka, Harutoshi</creatorcontrib><creatorcontrib>Sadato, Norihiro</creatorcontrib><creatorcontrib>Yonekura, Yoshiharu</creatorcontrib><creatorcontrib>Okada, Kenichiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular imaging and biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oyama, Nobuyuki</au><au>Akino, Hironobu</au><au>Suzuki, Yuji</au><au>Kanamaru, Hiroshi</au><au>Miwa, Yoshiji</au><au>Tsuka, Harutoshi</au><au>Sadato, Norihiro</au><au>Yonekura, Yoshiharu</au><au>Okada, Kenichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Value of 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography Imaging for Patients with Prostate Cancer</atitle><jtitle>Molecular imaging and biology</jtitle><addtitle>Mol Imaging Biol</addtitle><date>2002</date><risdate>2002</risdate><volume>4</volume><issue>1</issue><spage>99</spage><epage>104</epage><pages>99-104</pages><issn>1536-1632</issn><eissn>1860-2002</eissn><abstract>Purpose: The purpose of this study was to investigate the prognostic value of measuring glucose metabolism of primary prostate cancer lesions, using 2-Deoxy-2-[F-18]Fluoro-D-Glucose positron emission tomography (FDG-PET).
Procedures: Forty-two patients with prostate cancer were investigated with FDG-PET, and standardized uptake value (SUV) of the prostate was calculated. After PET study, radical prostatectomy was performed in 17 patients (RPT group), and endocrine therapy in 25 patients (ET group). Relapse-free survival curves were created by the Kaplan-Meier method.
Results: In the RPT group, the patients with high SUV had a poorer prognosis compared to those with low SUV (
P = 0.033). In the ET group, the patients with high SUV were likely to have a poorer prognosis with low significance at a level of
P = 0.087.
Conclusions: FDG-PET appeared to have a defined prognostic value for patients with prostate cancer undergoing radical prostatectomy, and more patients need to be studied for patients undergoing endocrine therapy. (Mol Imag Biol 2002;4:99–104)</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>14538053</pmid><doi>10.1016/S1095-0397(01)00065-6</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1536-1632 |
| ispartof | Molecular imaging and biology, 2002, Vol.4 (1), p.99-104 |
| issn | 1536-1632 1860-2002 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72912467 |
| source | Alma/SFX Local Collection |
| subjects | FDG-PET Glucose Metabolism Prognosis Prostate Cancer |
| title | Prognostic Value of 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography Imaging for Patients with Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T06%3A47%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Value%20of%202-Deoxy-2-%5BF-18%5DFluoro-D-Glucose%20Positron%20Emission%20Tomography%20Imaging%20for%20Patients%20with%20Prostate%20Cancer&rft.jtitle=Molecular%20imaging%20and%20biology&rft.au=Oyama,%20Nobuyuki&rft.date=2002&rft.volume=4&rft.issue=1&rft.spage=99&rft.epage=104&rft.pages=99-104&rft.issn=1536-1632&rft.eissn=1860-2002&rft_id=info:doi/10.1016/S1095-0397(01)00065-6&rft_dat=%3Cproquest_cross%3E72912467%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72912467&rft_id=info:pmid/14538053&rft_els_id=S1095039701000656&rfr_iscdi=true |